What this is
- How it works
- Tubulin-binding agent
- How it’s given
- “Plinabulin will be administered by IV infusion at 30 mg/m² over approximately 1 hour on Days 1 and 8 of each 21-day treatment cycle. On Day 1, plinabulin will be administered approximately 1 hour after completion of the docetaxel infusion.”In the company’s words, NCT07361484 on ClinicalTrials.gov
- Tested for
- Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance
- Main trialPhase 3
- “This is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating docetaxel plus plinabulin versus docetaxel plus placebo in participants with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without EGFR, ALK, ROS1, or RET alterations who have experienced disease progression after prior anti-PD-1/PD-L1 immunotherapy and platinum-based chemotherapy. Approximately 442 participants will be randomized 1:1 to receive docetaxel (75 mg/m² IV on Day 1 of each 21-day cycle) in combination with plinabulin (30 mg/m² IV on Days 1 and 8) or…”In the company’s words, NCT07361484 on ClinicalTrials.gov
- Other names
- NPI-2358 · BPI-2358
Coming up1
- 1 Jun 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 1 Jun 2029 | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) | |
| Phase 3Completed | 12 Dec 2018 | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 | |
| Phase 3Unknown | 25 Sep 2020 | Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia | |
| Phase 3Completed | 21 Jul 2021 | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC | |
| Phase 2Completed | 20 Mar 2018 | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026